{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:03:35Z","timestamp":1790633015309,"version":"4.1.0"},"reference-count":78,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiology"],"published-print":{"date-parts":[[2024,4,12]]},"DOI":"10.2217\/fmb-2023-0197","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T15:17:07Z","timestamp":1705936627000},"page":"465-480","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Perspectives on the use of ceftolozane\/tazobactam: a review of clinical trial data and real-world evidence"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-4063","authenticated-orcid":false,"given":"Ignacio","family":"Martin-Loeches","sequence":"first","affiliation":[{"name":"Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James's Hospital, Dublin, D08 NHY1, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Bruno","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway 07065, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Andrew","family":"DeRyke","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway 07065, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30605-4"},{"key":"e_1_3_5_5_1","unstructured":"Antibiotic resistance threats in the United States (2019). https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf (May 9)."},{"key":"e_1_3_5_6_1","unstructured":"Antibiotic resistance. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antibiotic-resistance (June 9)."},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/652237"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_5_10_1","unstructured":"WHO publishes list of bacteria for which new antibiotics are urgently needed. https:\/\/www.who.int\/news-room\/detail\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (May 11)."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab252"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0926-5"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306801"},{"key":"e_1_3_5_14_1","volume-title":"StatPearls [Internet].","author":"Shebl E","year":"2023","unstructured":"Shebl E, Gulick PG. Nosocomial pneumonia. In: StatPearls [Internet]. StatPearls Publishing (2023)."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1712"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.46.1800516"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-021-02135-z"},{"issue":"2","key":"e_1_3_5_18_1","first-page":"ofac492","article-title":"Activity of ceftolozane\/tazobactam and comparators against clinical MDR and DTR Pseudomonas aeruginosa isolates \u2013 SMART United States 2018\u20132020","volume":"9","author":"Lob S","year":"2022","unstructured":"Lob S, Hackel M, Siddiqui F et al. Activity of ceftolozane\/tazobactam and comparators against clinical MDR and DTR Pseudomonas aeruginosa isolates \u2013 SMART United States 2018\u20132020. Open Forum Infect Dis 9(Suppl. 2), ofac492 (2022).","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab320"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115172"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.1304"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914433"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa381"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4733-4738.2005"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2016.01020"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fux020"},{"issue":"4","key":"e_1_3_5_27_1","doi-asserted-by":"crossref","first-page":"e00500","DOI":"10.1128\/mBio.00500-17","article-title":"Metabolic compensation of fitness costs is a general outcome for antibiotic-resistant Pseudomonas aeruginosa mutants overexpressing efflux pumps","volume":"8","author":"Olivares Pacheco J","year":"2017","unstructured":"Olivares Pacheco J, Alvarez-Ortega C, Alcalde Rico M, Martinez JL. Metabolic compensation of fitness costs is a general outcome for antibiotic-resistant Pseudomonas aeruginosa mutants overexpressing efflux pumps. mBio 8(4), e00500\u201300517 (2017).","journal-title":"mBio"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7890"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.2080"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02177-19"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1187"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2018.11.009"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-014-0596-8"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01061-7"},{"issue":"3","key":"e_1_3_5_35_1","article-title":"Antimicrobial pharmacokinetics and pharmacodynamics in critical care: adjusting the dose in extracorporeal circulation and to prevent the genesis of multiresistant bacteria","volume":"12","author":"Ruiz-Ramos J","year":"2023","unstructured":"Ruiz-Ramos J, Gras-Mart\u00edn L, Ram\u00edrez P. Antimicrobial pharmacokinetics and pharmacodynamics in critical care: adjusting the dose in extracorporeal circulation and to prevent the genesis of multiresistant bacteria. Antibiotics (Basel) 12(3), (2023).","journal-title":"Antibiotics (Basel)"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac184"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2600"},{"key":"e_1_3_5_38_1","unstructured":"Zerbaxa 1 g\/0.5 g powder for concentrate for solution for infusion - Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zerbaxa-epar-product-information_en.pdf (March 30)."},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy280"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03681-14"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa139"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa049"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.019"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1733"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2165"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30403-7"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ097"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62220-0"},{"key":"e_1_3_5_49_1","unstructured":"ZERBAXA\u00ae Prescribing Information. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zerbaxa\/zerbaxa_pi.pdf (May 26)."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.08.003"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2018.10.012"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03074-15"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2018.10.009"},{"issue":"3","key":"e_1_3_5_54_1","first-page":"900","article-title":"Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane\/tazobactam","volume":"72","author":"Kullar R","year":"2017","unstructured":"Kullar R, Wagenlehner FM, Popejoy MW, Long J, Yu B, Goldstein EJ. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane\/tazobactam. J. Antimicrob. Chemother. 72(3), 900\u2013905 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_5_55_1","unstructured":"ZERBAXA\u00ae (ceftolozane\/tazobactam) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/206829s008lbl.pdf (June 9)."},{"key":"e_1_3_5_56_1","unstructured":"Safety and efficacy study of ceftolozane\/tazobactam to treat ventilated nosocomial pneumonia (MK-7625A-008) (ASPECT-NP). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02070757 (March 21)."},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics9030036"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03773-5"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00731-20"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000867"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy578"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03694-3"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04192-w"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106278"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab494"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12163"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1663827"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw374"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-022-01084-8"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00491-x"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy280"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-021-00933-8"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz816"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac079"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02340-18"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab089"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-023-07210-9"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00582-2017"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2194"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2023-0197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T16:37:28Z","timestamp":1727195848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2023-0197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,4,12]]}},"alternative-id":["10.2217\/fmb-2023-0197"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2023-0197","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}